Project 451329
A bioprocess that optimizes safe Human iPSCs for the treatment of osteoporotic fractures
A bioprocess that optimizes safe Human iPSCs for the treatment of osteoporotic fractures
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Krawetz, Roman J |
| Co-Investigator(s): | Edwards, W. Brent; Kallos, Michael S |
| Institution: | University of Calgary |
| CIHR Institute: | Musculoskeletal Health and Arthritis |
| Program: | |
| Peer Review Committee: | Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage |
| Competition Year: | 2021 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Throughout the lifespan, bone remodels in response to damage, such as fracture. However, diseases such as osteoporosis can cause impaired bone healing, increasing the risk of progression to non-repairing defects called fracture non-unions. Promoting the healing of fracture non-unions is a promising target for bone tissue engineering due to the limited success of current clinical treatment methods in patients with poor bone quality. However, there are still two main roadblocks in translating pluripotent stem cell (PSC) therapies into the clinic are: 1.) Incomplete differentiation leading to tumor formation and 2.) Clinically insufficient cell numbers. Our team has formulated a solution to both of these problems and will apply our safe PSC therapy to osteoporotic fracture repair, which is a global health concern with 1 in 4 Canadians suffering from an osteoporotic fracture in their lifetime. The outcomes of this study provide fundamental knowledge required for developing safe and effective stem cell therapies to treat bone fractures in patients with osteoporosis.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.